Pasireotide Drugs Market Trends, Size, Competitive Analysis and Forecast 2021-2027
The global Pasireotide drugs market is estimated to grow at a significant CAGR during the forecast period. Pasireotide is used for the treatment of a certain condition (acromegaly) occurring when the body produces too much of a particular natural substance called growth hormone. Acromegaly treatment helps to reduce the risk of severe problems such as diabetes and cardiac disease. Pasireotide works by reducing the growth hormone produced in the body. Pasireotide is also used for the treatment of a specific condition (Cushing's disease) when surgery is not successful or cannot be used to correct the condition.
To Request a Sample of our
Report on Pasireotide Drugs Market: https://www.omrglobal.com/request-sample/pasireotide-drugs-market
Increasing public awareness of
how to address this rare disease, combined with a high prevalence of
acromegaly, is likely to boost demand for Pasireoside for treatment, and this
will propel the global Pasireotide market. Several U.S. agencies, such as the
National Centre for Advancing Translational Sciences (NCATS) and the National
Institutes of Health (NIH), supply inexpensive medications for rare disorders
such as acromegaly. According to the national science centre in January 2021,
the number of rare diseases in the world is estimated at 6000 to 8000, with new
and unusually occurring diseases being regularly described in the medical
literature. However, 80% of all people with rare illnesses were affected by
around 350 rare diseases.
Some major market players include Hoffmann La Roche, Ltd., International GmbH., Boehringer Ingelheim., Novartis AG., and Ipsen Group, among other. In June 2020, Chiasma received FDA approvals for MYCAPSSA in patients who have responded to acromegaly and have tolerated treatment with octreotide or lanreotide for long-term maintenance therapy. For commercial purposes, MYCAPSSA is the first and only analogue oral somatostatin approved by the FDA. The FDA approved Mycapssa as an oral version of somatostatin analogues, a group of injecting a drug that slows growth hormone overproduction that leads to serious complications in acromegaly patients. Every year, there are about 8,000 U.S. patients treated with analogue somatostatin.
Market Coverage
·
The market number
available for – 2020-2027
·
Base year- 2020
·
Forecast period-
2021-2027
Segments Covered
·
By Type
·
By Application
Regions Covered
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
·
Competitive
Landscape- Hoffmann La Roche, Ltd., International GmbH., Boehringer Ingelheim.,
Novartis AG., and Ipsen Group.
(Get 15% Discount on Buying
this Report)
A full Report of Pasireotide
Drugs Market is Available at: https://www.omrglobal.com/industry-reports/pasireotide-drugs-market
Regional
Analysis
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons
to buy from us –
1.
We cover more than 15 major industries, further segmented into more than 90
sectors.
2.
More than 120 countries are for analysis.
3.
Over 100+ paid data sources mined for investigation.
4.
Our expert research analysts answer all your questions before and after
purchasing your report.
For
More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pasireotide-drugs-market
About Orion
Market Research
Orion Market Research (OMR) is a market research and consulting
company known for its crisp and concise reports. The company is equipped with
an experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments
Post a Comment